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Peripheral CD8þ T Cell Tolerance Against Melanocytic Self-
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Experimental evidence has suggested a role for CD8þ cytotoxic T lymphocytes (CTL) in the pathophysiology of
vitiligo, a pigmentation disorder with focal loss of melanocytes in the skin. The discovery of tyrosinase-related
protein 2 (TRP2) as a model melanocytic self-antigen recognized by CD8þ CTL in C57BL/6 mice allowed us to
analyze the requirements for CD8þ T cell-mediated autoimmune destruction of melanocytes in an experimental
model. Using two different genetic methods for the induction of cellular immunity in vivo, gene gun bombardment
of the skin and injection of recombinant adenovirus, we show that peripheral tolerance of CD8þ T cells recognizing
a single TRP2-derived H2-Kb-binding peptide is regulated in two steps. In the induction phase, stimulation and
expansion of TRP2-specific CD8þ T cells in vivo depend on CD4þ T cell help. In the effector phase, autoimmune
destruction of melanocytes in the skin depends on local inﬂammation. Our results suggest that accidental stim-
ulation of CD8þ CTL recognizing major histocompatibility complex class I-binding peptides derived from me-
lanocytic proteins in the context of an inﬂammatory skin disease may play an important role in the pathophysiology
of vitiligo.
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Vitiligo is a common pigmentation disorder where me-
lanocytes are focally destroyed in the skin. The association
with other autoimmune diseases suggests immunological
pathomechanisms in vitiligo (Berd et al, 1996; Dittmar and
Kahaly, 2003). To support this hypothesis, autoantibodies to
melanosomal proteins such as the tyrosinase family of en-
zymes have been detected in the serum of patients with
vitiligo (Song et al, 1994; Cui and Bystryn, 1995; Baharav
et al, 1996; Fishman et al, 1997; Kemp et al, 1997). More
recently, autoreactive CD8þ cytotoxic T lymphocytes
(CTL), which specifically recognize melanocytic differentia-
tion antigens, were demonstrated in perilesional skin and in
the peripheral blood (Ogg et al, 1998; Lang et al, 2001; Le
Gal et al, 2001; Palermo et al, 2001; Mandelcorn-Morson
et al, 2003). Melanocyte-specific CTL have been identified
in patients with melanoma where vitiligo may occur during
immunotherapeutic intervention (Scheibenbogen et al,
1994; Rosenberg and White, 1996; Rosenberg, 1997; Oka-
moto et al, 1998). Importantly, adoptive transfer of me-
lanoma antigen-specific cytotoxic T lymphocytes may be
associated with the regression of melanoma metastases
and the appearance of vitiligo, thus providing direct evi-
dence of T cell-mediated vitiligo in humans (Yee et al, 2000;
Dudley et al, 2002).
Experiments in murine models were also able to dem-
onstrate that CD8þ CTL recognizing shared lineage-spe-
cific melanocytic self-antigens such as tyrosinase or the
tyrosinase-related protein 2 (TRP2) can cause autoimmune
destruction of melanocytes leading to vitiligo-like fur
depigmentation (Bowne et al, 1999; Overwijk et al, 1999;
Colella et al, 2000; Steitz et al, 2000). The induction
and regulation of melanocyte-specific CTL are not well
understood. Clearly, mechanisms maintaining peripheral
self-tolerance must control potentially autoreactive, me-
lanocyte-specific CTL in vivo. This could be directly dem-
onstrated by immunization of tyrosinase gene knockout
albino and wild-type mice against the enzyme tyrosinase
where strong CTL responses could be stimulated in tyros-
inase-deficient mice, whereas only very weak reactivity was
observed in wild-type mice (Colella et al, 2000). Our group
previously reported that the in vivo induction of TRP2-spe-
cific CD8þ T cells using novel genetic immunization tech-
niques was only successful when TRP2 was linked to
foreign helper determinants (Steitz et al, 2002).
In this study, we wished to analyze the requirements for
CD8þ T cell-mediated autoimmune destruction of me-
lanocytes in C57BL/6 mice in greater detail. Using the gene
gun and recombinant adenoviruses—two fundamentally
different genetic approaches for the induction of cellular
immunity in vivo—we provide evidence that peripheral tol-
erance of CD8þ CTL recognizing melanocytic self antigens
is regulated in two steps: (1) the primary stimulation of
Abbreviations: Ad, recombinant adenovirus; EGFP, enhanced
green fluorescent protein; TRP2, tyrosinase-related protein 2
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potentially autoreactive CD8þ T cells in the lymphoid sys-
tem depends on CD4þ T cell help in the induction phase
and (2) the local autoimmune destruction of melanocytes in
the skin requires a strong inflammatory stimulus in the ef-
fector phase.
Results
Construction of expression plasmids encoding fusion
proteins between enhanced green ﬂuorescent protein
(EGFP) and deﬁned amino acid sequences of murine
TRP2 We previously showed that effective stimulation of
TRP2aa180–188 peptide-specific CD8þ T cells with genetic
immunization strategies required linkage of the weakly
immunogenic TRP2 with strong helper determinants. Fol-
lowing bombardment of the abdominal skin with plasmid
DNA encoding a fusion protein between TRP2 and the
immunogenic marker protein EGFP using the gene gun, we
observed in vivo stimulation and expansion of TRP2aa180–188
peptide-specific CD8þ T cells associated with vitiligo-like
fur depigmentation (Steitz et al, 2002). In contrast, immu-
nization with unmodified murine TRP2 only very rarely in-
duced significant T cell reactivity or coat color changes. But
in these experiments we could not establish a direct rela-
tionship between TRP2aa180–188 peptide-specific CD8þ T
cells and vitiligo because full-length TRP2 encoding aa30–
519 fused in frame to EGFP was used for immunization. To
specifically address the role of CD8þ T cells recognizing
the TRP2aa180–188 peptide for the induction of autoimmune
vitiligo, we then constructed plasmid DNA encoding fusion
proteins between EGFP and the truncated sequences
aa30–188, aa30–179, or aa180–188 of murine TRP2 (Fig
1A). These fragments of TRP2 were generated by PCR, se-
quenced to exclude mutations, joined in frame to the C-
terminal end of EGFP, and inserted into an expression
plasmid containing a CMV immediate-early promotor and
an SV40 polyadenylation signal. Expression of EGFP by all
constructs was confirmed in transiently transfected 293 cells
in vitro by fluorescence microscopy. Additionally, the size of
the fusion proteins was verified by western blot analyses of
lysates from transiently transfected 293 cells (Fig 1B).
Stimulation of CD8þ T cells in vivo and induction of
autoimmune vitiligo following gene gun immunization
with plasmid DNA containing a single H2-Kb-binding
peptide derived from the melanocytic protein TRP2 In
subsequent experiments, we tested the newly constructed
expression plasmids encoding the various fusion proteins
for their ability to stimulate TRP2aa180–188 peptide-specific
CD8þ T cells in vivo and induce autoimmune vitiligo in
the skin. Groups of 6 C57BL/6 mice were shaved on
the abdomen and bombarded with the expression plasm-
ids pCMV-EGFP.TRP2aa30–519, pCMV-EGFP.mTRP2aa30–188,
pCMV-EGFP.mTRP2aa30–179, pCMV-EGFP.mTRP2aa180–188,
or pCMV-EGFP using the gene gun on a weekly basis for
5 wk. Two mice of each group were sacrificed 1 wk after the
fifth immunization to analyze induction of antigen-specific
CTL in vivo. To this end, we tested splenocytes in interferon
(IFN)g-ELISPOT assays for recognition of the synthetic H2-
Kb-binding peptides TRP2aa180–188 and medium control.
As expected, immunization with plasmid DNA encoding
the truncated fusion proteins EGFP.mTRP2aa30–188 or
EGFP.mTRP2aa180–188 stimulated TRP2aa180–188 peptide-
specific CD8þ T-cells in vivo as effective as immunization
with plasmid DNA encoding full-length EGFP.TRP2aa30–519
(Fig 2A). The remaining four mice of each group were mon-
itored for the appearance of fur depigmentation. All mice
that had been immunized with plasmid DNA containing the
immunogenic EGFP and the TRP2aa180–188 peptide eventu-
ally developed autoimmune vitiligo on the site of gene gun
bombardment on the abdomen within a few weeks after the
last immunization (Fig 2B and C). Importantly, bombardment
of the skin with the plasmid expressing the TRP2aa180–188
peptide epitope attached to the C-terminus of EGFP effec-
tively induced vitiligo-like coat color changes, demonstrat-
ing that CD8þ T cells specific for a single and apparently
dominant H2-Kb-binding peptide epitope derived from
TRP2 are able to destroy melanocytes in the epidermal
layers of the hair follicle. Presumably, CD4 helper T cells
recognizing the immunogenic marker protein EGFP provide
linked help for the induction of TRP2aa180–188-specific
CD8þ cytotoxic T cells. To support this hypothesis, we
Figure1
Expression plasmids and recombinant adenoviruses expressing
C-terminal fusion proteins between enhanced green fluorescent
protein (EGFP) and defined amino acid sequences of murine
tyrosine-related protein 2 (TRP2). (A) The construction schemes of
the expression plasmids pCMV-EGFP.TRP2aa30–519, pCMV-EGFP.mTR-
P2aa30–188, pCMV-EGFP.mTRP2aa30–179, and pCMV-EGFP.mTRP2aa180–
188 used in this study are depicted. (B) Additionally, recombinant
adenoviruses were generated expressing these fusion proteins and
transgene expression verified by probing lysates of infected 293 cells in
western blots with EGFP-specific antibodies.
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genetically immunized groups of CD4-deficient C57BL/6 mice
with the expression plasmids pCMV-EGFP.mTRP2aa180–188
or pCMV-EGFP. None of the 8 CD4-deficient mice investi-
gated in two independent experiments developed vitiligo-
like coat color changes, indicating the need for CD4þ T cell
help during the induction phase of the immune response.
Furthermore, depletion of CD4þ T cells during the priming
phase completely prevented the induction of TRP2aa180–188-
specific CD8þ T cells in vivo (data not shown).
Inﬂuence of a competitively H2-Kb-binding epitope in
the helper determinant It is conceivable that competitively
H2-Kb-binding epitopes in the helper determinant may in-
fluence the immunogenicity of the weakly immunogenic
self-epitope derived from TRP2. Therefore, we constructed
plasmid DNA encoding for the TRP2aa180–188 peptide at-
tached in frame to the C-terminus of the immunogenic
marker protein b-galactosidase using PCR techniques and
inserted this sequence into the CMV-driven expression
plasmid pAdlox as described above. Escherichia coli b-ga-
lactosidase contains the strong H2-Kb-binding peptide epi-
tope bgalaa497–504. Expression of b-galactosidase by pCMV-
bgal.TRP2aa180–188 was confirmed in vitro by X-gal staining
of transiently transfected 293 cells. Groups of 6 C57BL/6
mice were shaved on the abdomen and bombarded
with the expression plasmids pCMV-bgal.TRP2aa180–188 or
pCMV-bgal as a control using the gene gun on a weekly
basis for 5 wk. Again, two mice of each group were sac-
rificed 1 wk after the third immunization to analyze induction
of antigen-specific CTL in vivo using the IFNg-ELISPOT
technique. Mice immunized with pCMV-bgal.TRP2aa180–188
showed reactivity for both the TRP2aa180–188 and the
bgalaa497–504 peptide (Fig 3A). The remaining mice were
again monitored for coat color changes. As expected, all
mice immunized with plasmid DNA expressing the fusion
protein bgal.TRP2aa180–188 developed vitiligo-like fur depig-
mentation (Fig 3B). This result provides some experimental
evidence that a strong competitively H2-Kb-binding epitope
in an immunogenic protein such as b-galactosidase does
not interfere with the ability to stimulate CD8þ T cells
in vivo specific for the attached TRP2aa180–188 peptide and
precipitate autoimmune vitiligo. Thus, any foreign protein
that accidentally contains a major histocompatibility com-
plex (MHC) class I peptide sequence with similarity to a
melanocytic self-antigen and is presented to the immune
system in an immunogenic way may stimulate cross-reac-
tive cytotoxic T cells that are potentially able to destroy
melanocytes in the skin.
Local inﬂammation in the skin is required for auto-
immune destruction of melanocytes in the effector
phase We previously observed that the injection of recom-
binant adenoviruses encoding for the fusion protein
EGFP.TRP2aa30–519 only very rarely led to vitiligo-like fur
depigmentation despite strong stimulation of TRP2aa180–188
peptide-reactive CD8þ T cells in vivo, which were associ-
ated with protective immunity against experimentally in-
duced melanoma metastases in the lungs (Steitz et al, 2002;
Fig 4A). In subsequent experiments, we combined the in-
jection of recombinant adenovirus with gene gun bombard-
ment of the skin. Groups of six wild-type mice were injected
Figure 2
Induction of autoreactive CD8þ T cells specific for the H2-Kb-
binding peptide SVYDFFVWL corresponding to aa180–188 of
tyrosine-related protein 2 (TRP2) using the gene gun leads to au-
toimmune destruction of melanocytes resulting in vitiligo-like fur
depigmentation. Groups of C57BL/6 mice were immunized by parti-
cle-mediated bombardment of the skin with the indicated plasmid
DNA. (A) Splenocytes were harvested after immunization and release of
IFNg in response to the H-2Kb-binding TRP2aa180–188 peptide tested
using ELISPOT assays. Results are expressed as mean number of spot
forming cells per 106 splenocytes. These data are representative
of three to five independent experiments. (B) Alternatively, mice
were followed for the appearance of vitiligo-like fur depigmentation.
The cumulative number of mice developing coat color changes
as a result of the immunization with the indicated plasmid DNA are
shown. (C) Representative pictures of mice immunized as indicated are
shown.
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intraperitoneally with 5  108 p.f.u. of the recombinant
adenoviruses Ad-EGFP.TRP2aa180–188 or Ad-bgal followed
after 1 and 2 wk with gene gun bombardment of the shaved
abdomen with the plasmids pCMV-EGFP.TRP2aa180–188 or
pCMV-bgal. Surprisingly, we observed very rapid appear-
ance of coat color changes in mice immunized with the
EGFP.TRP2aa180–188 fusion constructs. Depigmented fur
could be detected shortly after the second gene gun bom-
bardment (Fig 4B). Interestingly, Induction of CD8þ T cells
recognizing the TRP2aa180–188 peptide in vivo using the re-
combinant adenovirus Ad-EGFP.TRP2aa180–188 and gene
gun bombardment with the irrelevant expression plasmid
pCMV-bgal also efficiently promoted fur depigmentation,
indicating that local trauma and the associated inflamma-
tory response is sufficient to cause autoimmune destruction
of melanocytes in the skin. In subsequent experiments, we
verified this hypothesis by experimentally inducing a con-
tact allergy against Fluovio-2,6-dinitro-benzene (DNFB) in
combination with the injection of recombinant adenovirus.
Groups of mice were sensitized to DNFB 1 wk before the
injection with Ad-EGFP.TRP2aa180–188 or Ad-bgal. One week
later, mice were again treated with DNFB on the ears and
the abdomen to elicit the effector phase of contact allergy.
Again, depigmentation of fur could be detected within 2 wk
in areas of strong inflammation in the skin (Fig 4C).
Discussion
The involvement of potentially autoreactive antibodies and
cytotoxic T lymphocytes in the pathophysiology of vitiligo is
not completely understood. Recently, the application of
Figure 3
The presence of a strong competitively H2-Kb-binding epitope in
the fusion protein between tyrosine-related protein 2 (TRP2) and
Escherichia coli b-galactosidase did not impair the ability to stim-
ulate TRP2-specific CD8þ T cells and induce vitiligo. Groups of
C57BL/6 mice were immunized by particle-mediated bombardment of
the skin with the indicated plasmid DNA. (A) Splenocytes were har-
vested after immunization and release of IFNg in response to the H-
2Kb-binding TRP2aa180–188 peptide tested using ELISPOT assays. Re-
sults are expressed as mean number of spot forming cells per 106
splenocytes. These data are representative of three to five independent
experiments. (B) Alternatively, mice were followed for the appearance
of vitiligo-like fur depigmentation. The cumulative number of mice de-
veloping coat color changes as a result of the immunization with the
indicated plasmid DNA are shown.
Figure4
Local inflammation in the skin is required for autoimmune de-
struction of melanocytes by autoreactive CD8þ Tcells specific for
the tyrosine-related protein 2 (TRP2)aa180–188 peptide. Groups of
C57BL/6 mice were treated as indicated and followed for the appear-
ance of vitiligo-like fur depigmentation. (A) The cumulative number of
mice developing vitiligo-like fur depigmentation in response to intra-
peritoneal injection with the indicated recombinant adenoviruses are
shown. (B) The cumulative number of mice developing vitiligo-like fur
depigmentation in response to a combined immunization with the in-
dicated recombinant adenoviruses followed by particle-mediated bom-
bardment of the skin with the indicated plasmid DNA are shown. (C).
The cumulative number of mice developing vitiligo-like fur depigmen-
tation in response to immunization with recombinant adenovirus com-
bined with the experimental induction of contact allergy against DNFB
are shown.
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novel genetic immunization strategies for the induction of
antigen-specific immune responses against melanosomal
enzymes of the tyrosinase family has provided some insight
into the mechanisms regulating immunity and tolerance to
this category of antigens. Stimulation of antibodies as well
as CD4þ helper T cells specific for the brown locus protein
gp75/TRP1 has been associated with vitiligo-like fur depig-
mentation in C57BL/6 mice (Bowne et al, 1999; Overwijk
et al, 1999). Coat color changes were also observed fol-
lowing induction of CD8þ cytotoxic T cells specific for the
slaty locus protein TRP2 (Bowne et al, 1999; Steitz et al,
2000). However, vitiligo was not observed with several im-
munization strategies including the use of cultured dendritic
cells as biological adjuvant despite strong induction of pro-
tective immunity against B16 melanoma cells (Bronte et al,
2000; Schreurs et al, 2000; Steitz et al, 2001).
In our experiments, we directly addressed the role of
CD8þ CTL recognizing melanocytic self-antigens for the
induction of vitiligo. We constructed an expression plasmid
and a recombinant adenovirus that only encode the nine
amino acids SVYDFFVWL corresponding to the H2-Kb-
binding peptide epitope derived from aa180–188 of the
melanosomal enzyme TRP2 attached to the immunogenic
marker protein EGFP. This avoids the potential induction of
CD4þ Th cells and antibodies specific for TRP2. Several
lines of evidence demonstrate that the in vivo stimulation of
TRP2aa180–188-specific CD8þ CTL requires EGFP-specific
CD4þ T helper cells during the induction phase of the im-
mune response. Firstly, immunization of CD4-deficient mice
did not lead to vitiligo-like depigmentation. Secondly, injec-
tion of recombinant adenovirus encoding autologous
murine TRP2 followed by bombardment of the skin with
plasmid DNA encoding autologous murine TRP2 did not
stimulate TRP2aa180–188-specific CD8þ Tcells in vivo (Steitz
et al, 2000) and never led to autoimmune vitiligo in any of
the mice. In contrast, we consistently observed autoim-
mune vitiligo in almost every mouse when we intraperitone-
ally injected a recombinant adenovirus encoding fusion
proteins between EGFP and fragments of TRP2 containing
the TRP2aa180–188 epitope and subsequently bombarded
the skin with the gene gun. Thirdly, we could demonstrate
that the depletion of CD4þ T cells immediately before the
injection of recombinant adenoviruses abrogated in vivo
stimulation of TRP2aa180–188-specific CD8þ T cells.
Since TRP2aa180–188-specific CD8þ CTL precursors ob-
viously escape central deletion they must be regulated in
the peripheral immune organs. One possibility is that they
simply ignore their antigen in the skin under normal circum-
stances. This has been directly demonstrated in mice
transgenically expressing a TCR derived from CD8þ CTL
recognizing an altered peptide ligand to aa25–33 of the sil-
ver locus protein pmel17/gp100 (Overwijk et al, 2003). It is
also conceivable, however, that TRP2aa180–188-specific CTL
are actively controlled by regulatory T cells. Recently, it has
been shown that such regulatory cells may be stimulated by
immature dendritic cells (Hawiger et al, 2001). Indeed, im-
mature Langerhans cells from the epidermis constantly car-
ry melanosomal proteins to the lymph node (Stoitzner et al,
2002). Alternatively, tolerance mechanisms may also be ac-
quired during the neonatal period where CD8þ T cells have
been demonstrated to access the epidermis and become
functionally tolerant to peripherally expressed self-antigens
(Alferink et al, 1998). To overcome peripheral tolerance,
naı¨ve TRP2aa180–188-specific CTL need to be stimulated by
activated antigen-presenting dendritic cells. Interactions
with CD4þ Th cells mediated by additional signals such as
CD40–CD40L signaling leading to full maturation of dendri-
tic cells subsequently control the expansion and the effector
function of TRP2aa180–188-specific CTL.
Similar to other investigators, we found that effective in-
duction of TRP2aa180–188-specific CD8þ CTL in vivo is not
necessarily associated with vitiligo-like fur depigmentation.
Rather, autoimmune destruction of melanocytes appeared
to depend on the immunization strategy. Bombardment
of the skin with the expression plasmid encoding
EGFP.TRP2aa180–188 always led to vitiligo, whereas mice
immunized by intraperitoneal injection with the correspond-
ing recombinant adenovirus only rarely developed coat col-
or changes. Subsequent experiments combining both gene
transfer techniques revealed that autoimmune destruction
of melanocytes by activated TRP2aa180–188-specific CD8þ
CTL largely depended on the inflammatory stimulus in the
skin provided by the particle bombardment. Lane et al
(2004) recently also reported that vaccination-induced au-
toimmune vitiligo is initiated by some form of trauma in the
skin. In contrast to our experiments, however, they immu-
nize with full-length human TRP2 protein and therefore can-
not exclude responses by CD4þ Th cells and antibodies.
It is currently not exactly known how inflammation and
trauma in the skin promote autoimmune destruction of
melanocytes by vaccine-induced TRP2aa180–188-specific
CD8þ CTL. We hypothesize that the production of pro-
inflammatory cytokines and chemokines by activated
keratinocytes following local trauma or inflammation upreg-
ulates adhesion molecules on capillary venules, thereby fa-
cilitating lymphocyte homing to the skin and providing
access to antigen-expressing melanocytes in the hair folli-
cles. The inflammatory response might also expose me-
lanocytes to cytotoxic destruction by upregulating their MHC
expression, which is normally low to absent. Thus, activation
of self-reactive T cells can potentially cause autoimmunity if
there is a subsequent inflammatory event in the target tissue.
This issue is of great importance for the experimental devel-
opment of melanoma vaccines, since it implies that me-
lanoma cells may also be completely ignored by activated
pigment cell-specific CD8þ CTL unless an inflammatory
microenvironment is established in the tumor tissue.
Our results suggest that immunity and tolerance of
TRP2aa180–188-specific CD8þ CTL in mice are regulated in
two steps. In a first general step, stimulation and expansion
of melanocyte-specific CD8þ CTL in secondary lymphoid
tissue are controlled by CD4þ Th cells and dendritic cells.
In a second tissue-specific step, an inflammatory stimulus is
required to cause overt autoimmune destruction of me-
lanocytes in the skin. A similar observation was reported in
an experimental model of transplant tolerance where local
inflammation also controlled the rejection of skin grafts car-
rying a defined MHC class I alloantigen recognized by
transgenic CD8þ CTL (Limmer et al, 1998). We envision
the following possible pathophysiologic scenario for the
development of vitiligo: an infectious pathogen happens
to express a protein containing an MHC class I-binding
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peptide sequence with similarity to a melanocyte protein.
This has already been described in the human system,
where an HLA-A2-binding peptide epitope derived from the
Herpes simplex virus protein Glycoprotein C is very similar
to a HLA-A2-binding peptide epitope derived from the me-
lanocytic self-antigen MART1/MelanA. Antigen-specific
CD8þ T cells not only recognize infected cells but also
cross-react with melanocytes and melanoma cells (Loftus
et al, 1996). During active infection, the viral protein con-
taining the self-peptide is presented in an immunogenic
form and stimulates virus- and pigment cell-specific CD8þ
T cells. Subsequently, these T cells may be drawn into the
skin by an additional inflammatory stimulus. This can be a
minor form of trauma that could provide an explanation for
the clinical observation that vitiligo is frequently observed
on the hands. Alternatively, a strong sunburn that is not
infrequently reported by patients during the beginning and
progression of vitiligo could precipitate the autoimmune
destruction of melanocytes.
We are aware of the fact that our experimental model
only focuses on the role of pigment cell-specific CTL in the
pathogenesis of autoimmune vitiligo. Our experiments may
only in part represent the human condition where not only
cellular but also humoral immune responses to melanocytic
proteins have been extensively described in the serum of
many patients (Song et al, 1994; Cui and Bystryn, 1995;
Baharav et al, 1996; Fishman et al, 1997; Kemp et al, 1997).
Humoral immune responses have also been described to
induce autoimmune vitiligo with the melanocytic antigen
TRP1 in mice (Bowne et al, 1999). Thus the predominant
type of the immune response apparently depends on the
melanocytic self-antigen studied. Future investigations will
help to clarify this very interesting and important issue.
Materials and Methods
Animals, expression plasmids, and recombinant adenovirus-
es Six to 12 wk-old wild-type and CD4-deficient C57BL/6 mice (H-
2b) were bred at the Central Animal Facility of the University of
Bonn. Experiments were approved by the Rheinische Friedrich
Wilhelm University and the government of NRW Germany. The
institutional and national guide for the care and use of laboratory
animals was followed. Plasmids expressing fusion proteins between
the immunogenic helper determinants EGFP or b-galactosidase and
parts of murine TRP2 were constructed using standard PCR-tech-
niques, sequenced to exclude mutations introduced by PCR and
inserted into the adenoviral shuttle vector pAdlox containing a CMV
immediate-early promotor and a SV40 polyadenylation signal.
Plasmids were grown in E. coli strain DH5a and purified using Qia-
gen Plasmid Maxi Kits (Qiagen, Hilden, Germany). E1- and E3-
deleted adenoviral vectors expressing the fusion proteins were
generated through Cre-lox recombination with reagents generously
provided by Dr S. Hardy (Somatix, Alameda, California; Hardy et al,
1997). Adenoviruses were propagated on 293 cells, purified by
cesium chloride density gradient centrifugation and subsequent di-
alysis according to standard protocols, and stored at 701C.
Veriﬁcation of antigen expression Antigen expression was ver-
ified by fluorescence microscopy and immunoblotting. 293 cells
were either transfected with plasmid DNA using a standard CaPO4
precipitation in the presence of 25 mM of chloroquine for the first
10–16 h or infected with recombinant adenoviruses. The expres-
sion of EGFP could be directly confirmed in living cells by fluores-
cence microscopy. Alternatively, cells were solubilized after 48 h in
lysis buffer (20 mM Tris, 150 mM NaCl, 2 mM EDTA (ethylenedia-
minetetraacetic acid), 0.5% NP40, pH 7.5) containing protease
inhibitors (Complete Protease Inhibitor Cocktail, Boehringer,
Mannheim, Germany), subjected to a 10% SDS-PAGE, and elect-
roblotted onto PVDF membranes. Membranes were blocked with
5% non-fat dry milk in T-PBS (phosphate-buffered saline) (0.1%
Tween 20 in PBS) for 2 h and incubated with either a polyclonal
rabbit anti-TRP2 antibody (Pep8, kindly provided by Dr Vincent
Hearing, NIH, Bethesda, Maryland) or a polyclonal rabbit anti-EGFP
antibody (BD Biosciences/Clontech, Heidelberg, Germany) at a
1:400 dilution in T-PBSþ 2% non-fat dry milk for 1 h. Bound an-
tibodies were detected with 1:5000 dilutions of a peroxidase-con-
jugated goat anti-rabbit IgG antibody (Jackson Immunoresearch,
Westgrove, Pennsylvania) in T-PBSþ 2% non-fat dry milk for 1 h and
visualized using chemiluminescence on X-ray film (Amersham,
Freiburg, Germany).
Genetic immunization, induction of contact allergy, and eval-
uation of vitiligo Genetic immunization using the gene gun has
been performed as described previously (Steitz et al, 2000). Briefly,
plasmid DNA was precipitated onto 1.6 mm gold particles at a
density of 2 mg of DNA per mg of particles. For immunizations,
shaved skin of the abdomen was bombarded in vivo by two shots
with the Helios gene gun (BioRad, Munich, Germany) at a pressure
of 400 psi resulting in the delivery of approximately 1 mg gold
carrying 2 mg plasmid DNA. Immunizations were repeated weekly
for 5 wk. Genetic immunization with recombinant adenovirus was
performed by one intraperitoneal injection of 5  108 p.f.u. recom-
binant adenovirus resuspended in 0.2 mL PBS. In prime-boost
experiments, mice were first immunized with recombinant adeno-
virus and subsequently bombarded with plasmid DNA on day 7
and 14 as described above. For the experimental induction of a
contact allergy mice were sensitized on day 0 and 1 with 25 mL of a
0.5% DNFB in an acetone:oil (4:1) solution (Sigma, Munich, Ger-
many) painted on the shaved skin of the abdomen and ear. On day
7 sensitized mice were immunized recombinant adenovirus as de-
scribed above. On day 14 mice were challenged with 10 mL of a
0.2% DNFB solution in acetone:oil (4:1) painted on the shaved skin
of the abdomen and ear. The appearance of vitiligo-like fur depig-
mentation as a sign of autoimmune destruction of melanocytes
was evaluated weekly for 4 wk after the last immunization.
Peptides, ELISPOT assays The H-2Kb-binding peptide
SVYDFFVWL (TRP2aa180–188) derived from the murine melanosomal
protein TRP2 (Bloom et al, 1997) and the H-2Kb-binding peptide
ICPMYARV (bgalaa497–504) derived from E. coli b-galactosidase
(Brossart et al,1997) were purchased from GENOSPHERE (Paris,
France). Peptides were dissolved at 10 mg per mL in PBS containing
10% DMSO and stored at 201C. The induction of peptide-specific
T cells was measured using the ELISPOT technique. Briefly,
splenocytes were harvested 1 wk after the last immunization and
red blood cells depleted. 106 splenocytes per well were restimulated
in 200 mL of CM containing 1 mg per mL synthetic peptide and 25 IU
per mL rhIL-2 in Millipore HA plates, which were coated overnight
with 10 mg per mL (50 mL per well) of anti-mIFNg mAb (R4-6A2,
Pharmingen, Heidelberg, Germany) in PBS. After 22 h cells were
washed out of the plates and bound cytokines visualized by incu-
bation with 2.5 mg per mL (50 mL per well) of biotinylated anti-mIFNg
mAb (XMG1.2, Pharmingen) for 1.5 h at 371C, followed by 100 mL per
well streptavidin–peroxidase (Roche, Manheim, Germany, 1:1500
dilution in PBS containing 1% BSA, and 0.05% Tween 20) for 1/2 h at
RT, and premixed peroxidase substrate kit DAB (Vector Laboratories,
Heidelberg, Germany). The number of spots was counted using the
bioreader system (AIP, Strabberg, Germany) and expressed as mean
number of spots of repeated duplicate or triplicate determinations.
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